Polymyxin B hemoperfusion (PMX-F) for severe sepsis and septic shock

Hayashi, Y. (2012) Polymyxin B hemoperfusion (PMX-F) for severe sepsis and septic shock. Nihon Rinsho, 70 2: 311-314.

Author Hayashi, Y.
Title Polymyxin B hemoperfusion (PMX-F) for severe sepsis and septic shock
Formatted title
Language of Title jpn
Journal name Nihon Rinsho   Check publisher's open access policy
Language of Journal Name jpn
ISSN 0047-1852
Publication date 2012-02
Sub-type Article (original research)
Volume 70
Issue 2
Start page 311
End page 314
Total pages 4
Place of publication Osaka, Japan
Publisher Nipponrinsho
Collection year 2013
Language jpn
Abstract PMX-F, which was developed in Japan, is a potential therapeutic option for severe sepsis and septic shock. Despite positive effects on surrogate outcomes, demonstrated in methodologically suboptimal preliminary studies, its benefit on mortality remains unclear. Surprisingly, this expensive investigational therapy has been reimbursed by the Japanese National Health Insurance program since 1994 and 75,000 cartridges have been consumed, sometimes without expert intensive care supervision. Current evidence in intensive care medicine does not justify utilizing PMX-F for severe sepsis and septic shock, considering its unproven benefit, significant cost and potential risks. Even if reduced mortality is shown in future studies, that benefit could easily be cancelled out in settings, such as many Japanese institutions, where intensive care expertise is unavailable.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Tue, 12 Feb 2013, 11:52:15 EST by Mrs Maureen Pollard on behalf of Paediatrics & Child Health - RBWH